<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="74">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 22, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02122913</url>
  </required_header>
  <id_info>
    <org_study_id>LOXO-TRK-14001</org_study_id>
    <nct_id>NCT02122913</nct_id>
  </id_info>
  <brief_title>Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Adult Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of the Oral TRK Inhibitor LOXO-101 in Adult Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loxo Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loxo Oncology, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, Phase 1 study of orally administered LOXO-101 in adult
      subjects with advanced solid tumors that have progressed or are non responsive to available
      therapies and for which no standard or available curative therapy exists.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will be conducted in 2 parts: an initial dose escalation phase of LOXO-101 in
      subjects with advanced solid tumors. This will be followed by an expansion phase in solid
      tumor subjects with a neurotrophic tyrosine kinase receptor (NTRK) alteration. During the
      escalation phase, LOXO-101 will be taken once daily (QD) or twice daily (BID). During the
      expansion phase, the LOXO-101 dose selected from the escalation phase will be explored in
      30-60 additional subjects with an NTRK alteration.

      The objectives of the dose escalation phase are to determine the safety, tolerability,
      pharmacokinetic profile, and recommended dose of orally administered LOXO-101. The
      objectives of the expansion phase are to describe the preliminary anti-tumor activity of
      LOXO-101 in patients with NTRK alterations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD) and/or the appropriate dose for further clinical investigation.[Escalation]</measure>
    <time_frame>12 months [Estimated]</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rate [Expansion]</measure>
    <time_frame>12 months [Estimated]</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anti-tumor activity of LOXO-101 in subjects who have an NTRK alteration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of LOXO-101 including Cmax, Tmax, t1/2, and AUC following both QD and BID dosing.</measure>
    <time_frame>12 months [Estimated]</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 and 12 months [Estimated]</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression-free survival at 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum tolerated dose (MTD)</measure>
    <time_frame>12 months [Estimated]</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>LOXO-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation- Multiple doses of LOXO-101.
Expansion- The MTD dose of LOXO-101 achieved during the Escalation Phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LOXO-101</intervention_name>
    <description>Oral LOXO-101</description>
    <arm_group_label>LOXO-101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Escalation Phase [Inclusion]

          -  Locally advanced or metastatic adult solid tumor that has progressed or was
             nonresponsive to available therapies and for which no standard or available curative
             therapy exists;

          -  ECOG score of 0 or 1;

          -  Adequate hematologic, hepatic, and renal function;

        Escalation Phase [Exclusion]

        • Prior exposure to a selective TRK-blocking agent

        Expansion Phase [Inclusion]

          -  Escalation Phase inclusion criteria

          -  Tumor that is positive for NTRK1, NTRK2, or NTRK3 gene and/or TRKA, TRKB, or TRKC
             protein alteration

        Expansion Phase [Exclusion]

        • Escalation Phase exclusion criteria
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Cox, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Loxo Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carol Hill</last_name>
    <phone>+1 (650) 392-0004</phone>
    <email>Hill@loxooncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maegan Deegan</last_name>
    <phone>+1 (203) 998-5127</phone>
    <email>maegan@loxooncology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>11100</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>OHSU</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 26, 2016</lastchanged_date>
  <firstreceived_date>April 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TRK</keyword>
  <keyword>TRKA</keyword>
  <keyword>TRKB</keyword>
  <keyword>TRKC</keyword>
  <keyword>NTRK1</keyword>
  <keyword>NTRK2</keyword>
  <keyword>NTRK3</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
